(Q50209891)

English

Enasidenib: First Global Approval.

scientific article published on 6 September 2017

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

title

Enasidenib: First Global Approval. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

author name string

Esther S Kim

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

publication date

6 September 2017

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

published in

Drugs

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

volume

77

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

issue

15

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

page(s)

1705-1711

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

exact match

https://scigraph.springernature.com/pub.10.1007/s40265-017-0813-2

0 references

cites work

Isocitrate dehydrogenase mutations in myeloid malignancies

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-017-0813-2

retrieved

21 January 2018

Acute Myeloid Leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-017-0813-2

retrieved

21 January 2018

Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-017-0813-2

retrieved

21 January 2018

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-017-0813-2

retrieved

21 January 2018

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS40265-017-0813-2

retrieved

21 January 2018

Identifiers

DOI

10.1007/S40265-017-0813-2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

PubMed publication ID

28879540

1 reference

stated in

Europe PubMed Central

PubMed publication ID

28879540

retrieved

27 February 2018

reference URL

http://europepmc.org/abstract/MED/28879540

(Q50209891)

Enasidenib: First Global Approval.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)